Search | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 3 results.

- Speech
Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up.
Solal-Celigny, P. Imrie, K Belch, A Robinson, KS Cunningham, D. Rueda, A Catalano, J Offner, F. Walewski, J Raposo, J Smith, P. Marcus, R (2005) 47th Annual Meeting of the American-Society-of-Hematology — Atlanta(Ga)
- Speech
An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.
Marcus, R Imrie, K Belch, A Cunningham, D. Flores, E Catalano, J Solal-Celigny, P. Offner, F. Walewski, J Raposo, J Jack, A Smith, P. (2003) 45th Annual Meeting of the American-Society-of-Hematology — SAN DIEGO(California)
- Journal article
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
Marcus, R Imrie, K Belch, A Cunningham, D. Flores, E Catalano, J Solal-Celigny, P. Offner, F. Walewski, J Raposo, J Jack, A Smith, P. (2005) Blood — Vol. 105, no. 4, p. 1417-1423 (2005)